

# RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

RSC Advances

1

2 Encapsulation of food protein hydrolysates and peptides: a review

3

4 Aishwarya Mohan<sup>1</sup>, Subin R.C.K. Rajendran<sup>1</sup>, Quan Sophia He<sup>2</sup>, Laurent Bazinet<sup>3</sup>, Chibuike C.  
5 Udenigwe<sup>1,\*</sup>

6

7 <sup>1</sup>Food Functionality and Health Research Laboratory, Department of Environmental Sciences,  
8 Faculty of Agriculture, Dalhousie University, Truro, NS, B2N 5E3, Canada

9 <sup>2</sup>Department of Engineering, Faculty of Agriculture, Dalhousie University, Truro, NS, B2N 5E3,  
10 Canada

11 <sup>3</sup>Department of Food Science and Nutrition, and Institute of Nutrition and Functional Foods,  
12 Université Laval, Québec, Québec G1V 0A6, Canada

13

14 \*Corresponding author

15 E-mail: [cudenigwe@dal.ca](mailto:cudenigwe@dal.ca); Phone: +1 902 843-6625; Fax: +1 902 843-1404

16

17

18

19

20

RSC Advances

**21 Abstract**

22 Food protein hydrolysates and peptides are considered a category of promising functional food  
23 ingredients. However, commercial application of protein hydrolysates and their constituent  
24 peptides can be impeded by their low bioavailability, bitter taste, hygroscopicity and likelihood  
25 of interacting with the food matrix. Encapsulation as a delivery mechanism can be used to  
26 overcome these challenges for improving bioavailability and organoleptic properties of the  
27 peptides. Proteins, polysaccharides and lipids are the three carrier systems that have been utilized  
28 in food peptide encapsulation. The protein and polysaccharide systems mainly aim at masking  
29 the bitter taste and reducing hygroscopicity of protein hydrolysates, whereas the lipid-based  
30 systems are intended for use in enhancing bioavailability and biostability of encapsulated  
31 peptides. Spray drying technique is largely used to achieve microencapsulation in both protein  
32 and polysaccharide systems while, generally, liposomes are prepared by film hydration  
33 technique. However, it is seen that encapsulation efficiency (EE) of peptides using the liposome  
34 model is relatively lower since the entropy-driven liposome formation is uncontrolled and  
35 spontaneous. Achieving adequate EE through cost effective techniques is indispensable for  
36 encapsulation to be applicable to bioactive peptide-based product commercialization.  
37 Furthermore, the design of high quality functional foods requires detailed understanding of the  
38 release mechanism and kinetics, gastrointestinal stability, bioavailability and physiological  
39 bioactivity of the encapsulated peptide products.

40 **Keywords:** Encapsulation, Protein hydrolysate, Bioactive peptides, Biostability, Encapsulation  
41 efficiency

42

RSC Advances

43

**44 1.0. Introduction**

45 Encapsulation is the process of packaging solid, liquid or gaseous materials in capsules of  
46 different carriers, which release the active compounds (by diffusion, dissolution, pH trigger,  
47 degradation, etc.) at various intervals depending on the stability of the capsule.<sup>1</sup> The  
48 pharmaceutical industry has extensively used encapsulation technology in drug delivery to  
49 achieve precise, controlled, stable and targeted delivery of the drug. The food industry has also  
50 embraced the process of encapsulation to overcome certain challenges arising as a result of  
51 growing demand for functional ingredients in food.<sup>1</sup> This review is focused on bioactive food  
52 protein hydrolysates and peptides, whose incorporation into functional foods can be hindered by  
53 several challenges such as bitter taste, hygroscopicity, hydrophobicity, reaction with the food  
54 matrix, incompatibility, limited bioavailability, and biostability.<sup>2</sup> Biostability and bioavailability  
55 are pivotal for achieving physiological benefits as the peptides need to reach their targets intact  
56 in order to exert their bioactivity. Encapsulation has been used in the food industry and for  
57 delivery of several bioactive compounds that are sensitive to environmental factors, such as  
58 polyphenols, carotenoids and omega-fatty acids.<sup>3</sup> Nevertheless, encapsulation is yet to be applied  
59 in the commercial production of bioactive food protein hydrolysates and peptides.

60 Bioactive peptides are different from other food bioactive compounds such as vitamins or  
61 polyphenols in that the chemical species within the protein hydrolysates are highly  
62 heterogeneous.<sup>4</sup> Consequently, bioactive peptides may need to be isolated from more complex  
63 matrices or fractionated prior to encapsulation. Most studies on bioactive peptides are focused on  
64 the discovery of new bioactivity and protein precursors and elucidation of mechanisms with  
65 limited attention given to their biostability and bioavailability. Encapsulation can be explored for

RSC Advances

66 the delivery of bioactive food peptides; however, it is seen that optimum conditions for  
67 encapsulation of other compounds do not necessarily apply to bioactive peptides. Currently,  
68 there is a dearth of literature expounding various aspects of encapsulation in relation to food  
69 protein-derived bioactive peptides. Bioactive peptides are primarily encapsulated for the purpose  
70 of masking the bitter taste that result from exposure of taste receptors to hydrophobic amino acid  
71 residues generated from protein hydrolysis.<sup>5</sup> Another major objective of encapsulation is the  
72 reduction of hygroscopicity to ensure textural and storage stability of protein hydrolysates and  
73 peptides. Bioavailability and stability of the peptides are rarely investigated as major concerns  
74 despite strong evidence indicating that *in vitro* bioactivity are not always replicated in animal  
75 models and human subjects. The roles of several factors related to the process of encapsulation  
76 of food protein hydrolysates and peptides including the type of carrier system, method used for  
77 encapsulation, purity of wall/carrier material, core-to-wall ratio, and encapsulation conditions are  
78 still not clearly understood. This review highlights current advances in the process of  
79 encapsulation for food protein hydrolysates and peptides including factors that determine  
80 encapsulation efficiency (EE), and knowledge gaps that exist in the use of encapsulation for  
81 achieving the highest possible potential for food-derived bioactive peptides.

82

## 83 **2.0. Need for peptide encapsulation**

84 A primary challenge faced in translating food protein-derived bioactive peptides into commercial  
85 products is the susceptibility of peptides to gastrointestinal (GIT) digestion with the risk of losing  
86 their structural integrity and function when hydrolysed by GIT proteases and peptidases.<sup>2,6</sup>  
87 Bioavailability is used to depict the portion of the bioactive compound that is unchanged,  
88 absorbed and that reaches the systemic circulation.<sup>3</sup> Bioactive peptides, when orally

RSC Advances

89 administered, are subjected to peptic digestion in the stomach under acidic conditions,<sup>7</sup> followed  
90 by several alkaline pancreatic protease digestion in the intestinal phase before being absorbed  
91 through the enterocyte cells. It has been understood that oral ingestion of bioactive peptides will  
92 expose them to the action of at least 40 different enzymes before reaching systemic circulation.<sup>7</sup>  
93 Several studies have demonstrated that most food protein-derived bioactive peptides containing  
94 more than 2-3 amino acid residues do not withstand simulated gastrointestinal enzymatic  
95 digestion.<sup>7</sup> However, the bioactivity of some peptides have been retained or even increased  
96 following simulated GIT proteolytic activities. Particularly, dairy-derived antihypertensive  
97 tripeptides VPP and IPP, already commercially available for consumption through functional  
98 foods, are among the very few peptides that are reported to be stable following GIT digestion.  
99 Protecting bioactive peptides from physiological modifications is essential in translating *in vitro*  
100 activities in animal models and humans. Therefore, encapsulation has become a relevant and  
101 important technology for enhancing the utilization of food-derived bioactive peptides for human  
102 health promotion.

103

### 104 **3.0. Type of carrier systems for peptide encapsulation**

105 The food industry is restricted to the use of carrier matrices that are edible, biodegradable, non-  
106 toxic and inexpensive.<sup>3</sup> Although there are separate extensive reviews on lipids,<sup>8</sup>  
107 polysaccharides<sup>3</sup> and protein-based<sup>9</sup> carriers for encapsulation of food-derived bioactive  
108 compounds, there is a need to discuss the different carriers with particular focus on their use for  
109 encapsulating food protein hydrolysates and peptides (Fig. 1).

RSC Advances

110           **3.1. Protein-based carriers:** Encapsulation using the protein-based matrix is thought to  
111 be the most nutritionally beneficial system.<sup>10</sup> Despite the popularity of protein-based carriers for  
112 delivering other food bioactive compounds such as flavonoids, vitamins and  $\beta$ -carotene,<sup>9</sup> the use  
113 of protein carriers in bioactive peptide encapsulation is limited. Encapsulating bioactive core  
114 substance with a chemically similar material is challenging because of structural similarity; that  
115 is, the encapsulation shell is predicted to face instability issues similar to the encapsulated  
116 bioactive compound.<sup>5</sup> Recently, Wang *et al.* reported the use of native, acylated and high  
117 pressure-treated rapeseed protein isolate for the encapsulation of peptides derived from the same  
118 material.<sup>11</sup> The inclination towards the use of proteins for delivery of bioactive compounds is due  
119 their functional properties such as film and gel forming ability, emulsification and solubility, in  
120 addition to their nutritional benefit as sources of essential amino acids. Among the protein  
121 sources, soybean has been the predominant choice for bioactive peptide encapsulation (Table 1)  
122 whereas milk proteins are extensively used in the encapsulation of other non-peptide bioactives.<sup>9</sup>  
123 Milk caseins has been used for encapsulation of small hydrophobic compounds due their  
124 micellar structure in aqueous environment.<sup>12</sup> However, it appears that there is no clear rationale  
125 for selection of the protein carrier for food protein hydrolysate and peptide encapsulation. The  
126 encapsulation mechanism involving hydrophilic or hydrophobic interactions appear challenging  
127 to achieve with protein carriers considering the structural heterogeneity of the encapsulated  
128 peptide mixtures. Moreover, recent studies have reported successful encapsulation of dipeptide  
129 Phe-Trp and pentapeptide Leu-Trp-Met-Arg-Phe using  $\text{CaCl}_2$  cross-linked whey protein  
130 microbeads of 1-2 mm diameter, resulting in equilibrium constants of 2.3 and 37, respectively  
131 for the peptides.<sup>13,14</sup> This demonstrates that the peptides are more distributed in the protein  
132 microbeads compared to the aqueous phase, with higher distribution and EE observed for the

RSC Advances

133 pentapeptide. Although not extensively used as carriers for peptide encapsulation, milk proteins  
134 are well established as major sources of bioactive peptides. Furthermore, polysaccharides can be  
135 combined with the protein carriers to provide structural stability to the encapsulation (Table 1).  
136 Although a “top-down” approach, involving fragmentation of larger structures, has been  
137 proposed to accomplish nanoencapsulation,<sup>9</sup> only microencapsulation has been achieved to date  
138 when proteins are used for peptide encapsulation. Protein carriers have been shown to reduce the  
139 hygroscopicity of peptides,<sup>10,15</sup> although there are contrasting reports of increased hygroscopicity  
140 after encapsulation.<sup>5</sup> This variation could be attributed to physical and structural changes that can  
141 occur with the processing of proteins during encapsulation.

142 **3.2. Polysaccharide-based carriers:** Polysaccharides are generally ideal for use as  
143 delivery agents because they are structurally stable, abundant in nature and inexpensive. The  
144 reactive functional groups of polysaccharides make them one of the best choices as carrier  
145 matrix.<sup>3</sup> On the other hand, under extreme conditions, such as high temperature, the  
146 polysaccharide wall is susceptible to reacting with the peptide core to form complex products  
147 (e.g. Maillard reaction products), which can be potentially toxic and also deplete the bioactive  
148 peptides. In order to circumvent this challenge, the reactive functional groups of polysaccharides  
149 have been modified by processes such as carboxymethylation to produce relatively inert  
150 carriers.<sup>16</sup> The colossal molecular structure of polysaccharides contributes to their stability as  
151 carriers during production and processing of encapsulated products. Polysaccharides derived  
152 from plants, animals and microbial sources, such as gum arabic, chitosan, cyclodextrin and  
153 maltodextrin, have been utilised for food protein and peptide encapsulation (Table 1). Although  
154 polysaccharides are mostly used in combination with protein carriers, Yokota *et al.* used  
155 disaccharides as cryoprotectants in the liposome encapsulation model.<sup>17</sup> In the study, addition of



RSC Advances

156 disaccharides was found to reduce the EE and increase the particle size of the products.  
157 Furthermore, the amount of polysaccharide carriers used was found to positively correlate with  
158 particle size of the encapsulated products.<sup>18</sup>

159 **3.3. Lipid-based carriers:** Liposphere and liposome are two lipid-based systems that are  
160 currently used for encapsulating food protein hydrolysates and peptides. The former has a fatty  
161 acid inner layer and outer layer composed of the hydrophilic part of the fatty acid or  
162 phospholipid (PL), whereas the latter is a single or multiple concentric bilayer made of  
163 phospholipids constituting a vesicle.<sup>4</sup> Accordingly, lipospheres appear appropriate for  
164 encapsulating hydrophobic peptides that can interact with the hydrophobic inner layer of the  
165 carrier. A few studies have used lipospheres for the encapsulation of protein hydrolysates with  
166 moderate to high EE. For instance, a combination of stearic acid and phosphatidyl choline (PC)  
167 was used to encapsulate casein peptide fractions by the melt process, and this resulted in  
168 different (50-83%) EE, even when the samples possess similar surface hydrophobicity.<sup>19</sup> This  
169 suggest that the EE of peptides in lipospheres can be affected by other factors. Similar EE (74%)  
170 was also reported for CH encapsulation in multi-component lipid carrier (stearic acid/cupuacu  
171 butter/polysorbate 80).<sup>20</sup> Peptide encapsulation was found to not affect the thermal behaviour of  
172 the capsules<sup>20</sup> and no considerable oxidation was observed during a 60-day storage of the  
173 encapsulated products.<sup>19</sup> The latter can be attributed to the predominant composition of saturated  
174 stearic acid and absence or small amounts of oxidatively-labile unsaturated fatty acids in the  
175 spheres.

176 Liposome is a more popular encapsulation carrier compared to the liposphere, which  
177 would be less preferred for food applications because of its high saturated fatty acid content, and  
178 the limited choice of substances that can be incorporated in its highly hydrophobic core.

RSC Advances

179 However, liposome is compatible with a wide variety of bioactive peptides. The aqueous core  
180 appears suitable for hydrophilic peptides and other compounds, while the interior of the bilayer  
181 is compatible with hydrophobic peptides. Moreover, amphiphilic peptides can exist at the  
182 interface between the shell and core of the liposome structure, which would interact with the  
183 hydrophobic and hydrophilic amino acid residues, respectively.<sup>17</sup> Liposome is similar to cell  
184 membranes and is therefore favourable for the delivery of bioactive compounds, which can  
185 otherwise be degraded by the digestive physiological environment. PC is the commonly used  
186 phospholipid for liposome preparation. The large, commercial-scale production that is possible  
187 in the case of lipid carriers is a distinct advantage of liposomes over other carrier systems.<sup>8</sup>  
188 Liposomes adapted from the pharmaceutical industry have certain shortcomings in functional  
189 food application. Particularly, the thermal instability of liposome encapsulated food peptide  
190 products beyond the phase transition temperature of the phospholipid can limit their  
191 incorporation in thermally processed food. Besides, liposome preparation involves the use of  
192 cholesterol to increase the stability of the lipid bilayer, which is a health concern for application  
193 in functional foods. Yet another drawback of using liposome system in peptide encapsulation is  
194 the risk of lipid oxidation during production, processing and storage of the products.  
195 Consequently, the presence of lipids (especially unsaturated fatty acids) in the peptide-based  
196 functional foods can impact product shelf life and limit the choice of processing and storage  
197 conditions. Mild oxidation was reported for liposomes at high temperature and low pH,<sup>21</sup>  
198 although this needs to be reassessed when food protein hydrolysates and peptides are loaded in  
199 the capsules. Taken together, optimum conditions need to be developed to take advantage of the  
200 lipid-based system in food protein hydrolysate and peptide encapsulation considering the health

RSC Advances

201 and product quality challenges posed by the use of saturated and unsaturated lipids in lipospheres  
202 and liposomes, respectively.

203

#### 204 **4.0. Criteria for determining the quality of peptide encapsulation**

205 **4.1. Particle size:** The dispersibility and solubility of the encapsulated peptide product  
206 greatly depend on the particle size. Particle size of above 50  $\mu\text{m}$  can significantly affect the  
207 solubility, dispersion and hence, the texture and feel of the food.<sup>15</sup> Encapsulation products can be  
208 either of micro or nano scale. Nanoencapsulation is advantageous because of its high surface  
209 area that can increase the solubility and bioavailability of the product. It is thought that the  
210 smaller size of the capsules enhances delivery or release of the active molecules.<sup>8</sup> Among the  
211 various carriers, the lipid-based systems are more efficient for preparing nanoencapsulated  
212 protein hydrolysate and peptide products compared to the protein or polysaccharide systems.  
213 Due to their large molecular structure, most encapsulation involving protein and polysaccharide  
214 carriers, or a combination of both, results in the production of microcapsules. The combination  
215 of proteins and polysaccharides in encapsulation generates relatively large capsules, although all  
216 peptide encapsulation studies to date have yielded products with particle sizes under the  
217 threshold value of 50  $\mu\text{m}$  (Table 1). However, Zhang *et al.* produced 150-nm nanoencapsulated  
218 spirulina protein hydrolysates using chitosan as carrier.<sup>22</sup> Apart from the type of carrier, the  
219 particle size of the encapsulated peptide products also depends on the method used for  
220 encapsulation.<sup>9</sup> Yang *et al.*, in spite of using maltodextrin and cyclodextrin, were able to produce  
221 encapsulated products loaded with whey protein hydrolysates with particle sizes as small as 2.4  
222  $\mu\text{m}$  using the spray drying method.<sup>23</sup> Since spray drying is a destructive method of preparation, it  
223 is possible that the smaller particle size resulted from fragmentation of the capsules.

RSC Advances

224 Furthermore, the particle size of encapsulated peptides was found to depend on the core-to-wall  
225 ratio<sup>18</sup> (see section 5.3), but some studies have reported the absence of a particular trend.<sup>15,24</sup>

226 **4.2. Zeta potential:** Surface charge is one of the properties that convey the stability of  
227 encapsulated products. Stability enables the prediction of the behaviour of the encapsulated  
228 product in a food matrix. However, encapsulation performed for the purpose of masking the  
229 bitter taste of protein hydrolysates and peptides has not been focused on this surface property.  
230 Liposome-based encapsulation studies report high net negative zeta potential (surface charge)  
231 due to the presence of phospholipids, which have negatively charged hydrophilic heads. A  
232 decrease in the magnitude of the zeta potential would decrease the stability of the encapsulated  
233 product. Encapsulated protein hydrolysate and peptide products of low magnitude zeta potential  
234 have the tendency to aggregate in aqueous environment; a surface charge of  $\pm 30$  mV is essential  
235 to form stable dispersion due to electrostatic repulsion of the particles.<sup>25</sup> Encapsulation of  
236 peptides using chitosan yielded a product with a high positive surface charge of +41.5 mV.<sup>22</sup>  
237 Although there is limited knowledge on surface charge dynamics of encapsulated food protein  
238 hydrolysates and peptides, Mosquera *et al.* reported that simultaneously increasing the  
239 concentration of components of both the core (sea bream scale collagen peptide fraction) and the  
240 wall (PC) reduces zeta potential.<sup>24</sup> Most studies with polysaccharide and protein carriers did not  
241 report the zeta potential of the encapsulated protein hydrolysates and peptides. This information  
242 is particularly useful in evaluating the effects of the processing techniques utilized for these  
243 carriers, such as spray drying, on the encapsulated product stability. As discussed in section 5.4,  
244 mild processing techniques such as film hydration and ionotropic gelation have so far resulted in  
245 stable encapsulated products.<sup>22,24</sup>

RSC Advances

246           **4.3. Encapsulation efficiency:** EE can be defined as the amount of bioactive compound  
247 (peptide) trapped in the core or surface of the carrier compared to the initial amount of the  
248 bioactive material. *Zavareze et al.* measured EE of peptides indirectly by removing  
249 unencapsulated portion of the protein hydrolysate by centrifuging followed by estimation of  
250 peptide concentration using Lowry assay.<sup>25</sup> Membrane ultrafiltration has also been used to  
251 separate unencapsulated hydrolysate from the capsules prior to protein quantification.<sup>15</sup>  
252 Moreover, *Morais et al.* assessed the encapsulation rate of peptides in liposomes and lipospheres  
253 indirectly using second derivative spectrophotometry.<sup>26</sup> EE is an important factor to consider  
254 especially in producing commercial bioactive protein hydrolysate and peptide products.  
255 Although it was suggested that EE of over 50% increases the risk of leakage,<sup>8</sup> lower EE would  
256 lead to inefficient use of the bioactive materials and also imply that higher amount of  
257 encapsulated products would be required to attain the peptide quantities needed to exert  
258 physiological bioactivities. EE depends on the core-to-wall ratio, the conditions in which  
259 encapsulation is carried out, and encapsulation technique or production method utilized.<sup>9</sup> EE of  
260 microcapsules of protein hydrolysates and peptides prepared with polysaccharide carriers are  
261 occasionally reported (Table 1). Moreover, encapsulation using protein and polysaccharide  
262 carriers have resulted in higher EE compared to lipid-based (particularly liposome) peptide  
263 encapsulation (Table 1), possibly since the former is controlled and involves high energy  
264 processes in entrapping or encapsulating the peptides. Liposome formation involves entropy-  
265 driven, spontaneous and less controlled process. In general, techniques using high shear forces,  
266 pressure and high temperature result in higher EE, while mild preparation techniques such as  
267 film hydration and ionotropic gelation result in lower EE.

268

RSC Advances

## 269 **5.0. Factors that can affect encapsulation of peptides**

270 The chemistry of the encapsulated bioactive material fundamentally affects the EE. Although,  
271 there is limited comprehensive knowledge about the impact of peptide structure on  
272 encapsulation, EE is also thought to partly depend on some other factors (Fig. 2) as discussed  
273 below.

274 **5.1. Peptide charge:** Encapsulation of casein-derived peptides using liposomes mostly  
275 resulted in low EE (14%), which is attributable to the phosphoserine residues in  
276 caseinophosphopeptides (Mohan & Udenigwe, unpublished data). PL and the phosphopeptides  
277 are highly negatively charged leading to molecular repulsion and reduced encapsulation.  
278 Similarly, liposomal encapsulation of negatively charged intact bovine serum albumin has also  
279 been reported to result in low EE of 34%.<sup>27</sup> Higher EE values have been reported for the  
280 encapsulation of protein hydrolysates from other sources that lack the phosphoserine residues<sup>24</sup>,  
281 <sup>25</sup>, although the surface charge of the core materials was not reported.

282 **5.2. Type and purity of carrier/wall material:** Type and purity of carrier material are  
283 important factors that determine EE. High EE of 74-80% have been achieved using purified PC  
284 to form the liposomal carrier.<sup>24,25</sup> The small difference in EE can be due to the nature and  
285 different sources of the protein hydrolysates and peptides used for encapsulation. However,  
286 encapsulation of a similar protein hydrolysate with crude soy lecithin resulted in low EE of  
287 46%.<sup>15</sup> Similarly, in liposphere-based encapsulation studies, EE was no less than 50% and a  
288 maximum of 83% EE was obtained using purified PC and stearic acid.<sup>19, 26,28</sup> Conversely,  
289 comparable EE have been obtained when crude cupuacu butter was used with stearic acid in  
290 encapsulating casein peptide fractions.<sup>20</sup> The high EE of liposphere encapsulation can generally  
291 be attributed to the affinity of hydrophobic peptides in the core to the hydrophobic stearic acid

RSC Advances

292 inner layer (in contact with the core), although this mechanism entails the exclusion of  
293 hydrophilic (possibly bioactive) peptides from the capsule. Apart from casein peptides, there is a  
294 dearth of information on encapsulation of other protein hydrolysates and peptides using  
295 lipospheres making it challenging to draw conclusions on the prospects of the carrier system.  
296 Hydrophobic interaction has also been reported to increase EE for peptide encapsulation using  
297 microbeads prepared from whey protein isolate as the carrier; the study found a linear  
298 relationship between hydrophobic column capacity factor ( $k$ , depicting molecular  
299 hydrophobicity) and equilibrium constant ( $K$ ).<sup>13</sup> However, the study did not consider the role of  
300 peptide charge, which can also affect EE. Furthermore, acylation (by 47%) and high pressure  
301 treatment (200-400 MPa) of rapeseed protein isolate carrier resulted in high amount of secondary  
302 structure ( $\alpha$ -helix and  $\beta$ -sheet) and increased Young's modulus, which led to higher EE  
303 compared to the native and 5% hydrolyzed protein carrier.<sup>11</sup>

304 The advantage of using purified carrier materials is the reduction in the amount of  
305 materials needed to achieve high EE. Most polysaccharide-based encapsulation uses purified or  
306 synthetic carrier materials. Despite the consistently high EE, the use of high-purity wall materials  
307 in protein hydrolysate and peptide encapsulation does not appear to be economically feasible for  
308 the functional food industry,<sup>9</sup> except perhaps for the protein carriers. Obtaining or purifying the  
309 wall material would add significant step to the production process and can increase the input and  
310 product unit costs. There is a need for further research to identify and adapt processes that will  
311 lead to adequate EE for bioactive peptides without requiring high-cost input.

312 **5.3. Core-to-wall ratio:** Typically, encapsulation involves the use of large amounts of  
313 wall materials than the active core compounds. EE is largely influenced by the core-to-wall ratio  
314 and is found to always decrease with increase in the core concentration,<sup>22,24</sup> which can be due to

RSC Advances

315 overloading of the encapsulation system. Increase in the concentration of the wall material  
316 initially leads to increase in the EE until a certain point. For instance, Mosquera *et al.* reported a  
317 maximum EE of 74.6% at 1:31.5 (w/w) core-to-wall ratio (PC and sea bream scale protein  
318 hydrolysate);<sup>24</sup> the EE was found to decrease to 67% when the ratio was slightly changed to  
319 1:38.5 (w/w). Interestingly, Zavareze *et al.* achieved 80% EE of fish protein hydrolysate using a  
320 much lower core-to-wall (PC) ratio of 1:5 (w/w),<sup>25</sup> which suggests possible dependence of EE on  
321 the nature and molecular composition of the encapsulated material. However, Subtil *et al.* found  
322 that increase or decrease of the amounts of the wall (gum arabic) or core materials (casein  
323 hydrolysate) did not affect other characteristics such as the capsule morphology.<sup>29</sup> In contrast, a  
324 few studies involving protein and polysaccharide carriers have reported that varying the core-to-  
325 wall ratio increases the mean particle size and alters the morphology of the encapsulated protein  
326 hydrolysate and peptide products.<sup>11,18</sup> However, there has been no observable link between core-  
327 to-wall ratio and particle size for liposome-based encapsulated protein hydrolysates and  
328 peptides.<sup>24</sup> The lack of relationship between liposomal size and concentration of the core or wall  
329 can be partly attributed to difference in the process used in encapsulation. Furthermore, core-to-  
330 wall ratio increase from 1:2 to 2:1 was found increase the mean particle size and decrease the  
331 spray dry yield of peptide products encapsulated with rapeseed proteins.<sup>11</sup> Volume ratio of the  
332 core and wall material is also important in determining EE. A recent study reported that high EE  
333 (up to 95%) can be achieved by increasing the volume ratio of whey protein microbeads and  
334 peptides in aqueous solution ( $V_{\text{bead}}/V_{\text{aq}}$ ) from 0.013 to 0.2.<sup>13</sup> To date, commonly used core-to-  
335 wall ratios are 3:7 and 2:8 for protein and polysaccharide carriers and 1:(5-10) for liposome  
336 carriers (Table 1).



337 **5.4. Techniques used for encapsulation:** Currently, several techniques have been  
338 proposed for use in encapsulation of bioactive compounds such as coacervation, spray cooling,  
339 extrusion, supercritical fluid extraction, cocrystallization and inclusion.<sup>9</sup> Techniques involved in  
340 the nanoencapsulation of food ingredients utilizing lipid, protein and polysaccharide-based  
341 carrier systems have been extensively reviewed.<sup>3,8,9</sup> This review focuses only on the techniques  
342 currently applied and are relevant for encapsulation of food protein hydrolysates and peptides.

343 **5.4.1. Film hydration:** Liposome-based encapsulation of food protein hydrolysates and  
344 peptides mostly employs the film hydration technique. This option is popular due to the simple,  
345 yet effective mechanism where phospholipids self-assemble in response to energy input in the  
346 form of heat, agitation and sonication thereby trapping the aqueous core containing the peptides.  
347 The bilayer formation in liposome does not require the use of any sophisticated equipment  
348 except for the application of energy to drive the self-assembly. The disadvantage of liposome  
349 formation is that the uncontrolled assembly mechanism can lead to poor reproducibility and  
350 varying EE (Table 1). Moreover, organic solvents used in the liposomal encapsulation process  
351 need to be removed prior to use of the encapsulated products in functional foods, which  
352 introduces additional steps that can affect EE and the quality of the encapsulated products.

353 **5.4.2. Spray drying:** Both the protein and polysaccharide-based encapsulation frequently  
354 employs spray drying to achieve encapsulation due to the relatively low processing cost and ease  
355 of the technique.<sup>15</sup> This technique involves forming droplets and spraying at high temperature  
356 resulting in dried particles.<sup>18</sup> Unlike the liposome system, the spray drying process achieves  
357 entrapment of bioactives in the protein and polysaccharide carriers rather than having a distinct  
358 wall and core.<sup>15</sup> Spray drying has been found to result in microspheres with the active material  
359 uniformly distributed in the carrier, which typically occurs when the carrier and core materials

RSC Advances

360 are similarly hydrophilic.<sup>15</sup> This phenomenon is expected to lead to high EE although no study  
361 has yet reported the EE of spray dried encapsulated protein hydrolysate and peptide  
362 microcapsules (Table 1). Moreover, concavities on the microspheres produced through spray  
363 drying are commonly observed due to the rapid evaporation of the solvent.<sup>5,15,30</sup> However, the  
364 high temperature used during spray drying can lead to denaturation of protein carriers<sup>5</sup> and  
365 possibly alter peptide structure due to their reactivity. For instance, non-enzymatic browning can  
366 occur if considerable amount of reducing sugar is present in the system. Spray drying technique  
367 can be considered more appropriate for micro- rather than nanoencapsulation. Rocha *et al.*  
368 adapted spray drying for encapsulation of peptides in protein hydrolysates for functional food  
369 application, and also reported to have successfully incorporated the encapsulated product in  
370 protein bars.<sup>30</sup>

371 *5.4.3. Coacervation:* This technique is considered effective for encapsulation since it is  
372 based on electrostatic attraction between the core and wall materials. The technique involves  
373 phase separation and deposition of coacervate phase on the core.<sup>31</sup> Unlike other encapsulation  
374 methods, coacervation has been used to achieve EE of up to 91.6% using similar amounts of core  
375 (soy protein and pectin) and wall materials (casein hydrolysate).<sup>32</sup> The affinity between the core  
376 and wall due to surface properties contributed to the resulting high EE. One caveat with  
377 achieving such high affinity between the core and wall is that the peptides can be tightly bound  
378 to the extent that it becomes difficult to release them when needed. The wall material should  
379 have compatible (opposite) charge with the core to be able to coacervate. For instance, anionic  
380 polysaccharides such as gum arabic or alginate can be used to coacervate cationic peptides, and  
381 vice versa. Another technique used for peptide encapsulation include ionotropic gelation,<sup>22</sup>

RSC Advances

382 which is also a mild preparation method based on electrostatic interactions of the encapsulation  
383 materials.

384 **5.5. Production condition:** The peptide net charge is dependent on the pH of the medium  
385 during encapsulation, and this can influence the EE due to electrostatic effects. Encapsulation  
386 with both protein and polysaccharide-based carriers have been found to occur favourably at  
387 alkaline pH 8.<sup>5,15,32</sup> Moreover, Ruiz *et al.* reported that maximum EE was observed at pH 10 with  
388 dilute salt (CaCl<sub>2</sub>) solution while the least EE was observed at neutral pH and high salt  
389 concentration.<sup>16</sup> Conversely, liposome formation has been found to result in higher EE when  
390 conducted at neutral pH.<sup>17,24-26</sup> Taken together, the size of the encapsulated product is determined  
391 by production parameters and inherent properties of the wall and core materials such as energy  
392 input per unit mass, surface tension and density.

393

## 394 **6.0. Release and gastric stability of encapsulated peptides**

395 High affinity of the core and wall materials is paramount to the formation of stable encapsulated  
396 peptide products that can withstand food processing and storage conditions with limited diffusion  
397 losses of the core materials. Contrary to EE, a recent study demonstrated that the release kinetics  
398 of peptides encapsulated in protein microbeads in aqueous environment was inversely  
399 proportional to the peptide hydrophobicity with average release rate constants of 0.1 and 0.014  
400 min<sup>-1</sup> for Phe-Trp and Leu-Trp-Met-Arg-Phe, respectively, after 1 h.<sup>14</sup> Conversely, the  
401 modification of rapeseed protein by acylation and high pressure treatment that resulted in higher  
402 EE were found to increase the % release of the encapsulated peptide compared to the native  
403 protein after 24 h using the dynamic dialysis method.<sup>11</sup> This indicates weaker interaction of the

RSC Advances

404 peptides with the modified protein carrier. Although theoretically promising, the dearth of  
405 experimental information on the biostability of encapsulated protein hydrolysate and peptides  
406 makes it difficult to evaluate the prospects of encapsulation in oral delivery of bioactive peptides.  
407 A myriad of bioactive peptides derived from various food proteins have been reported and it is  
408 becoming increasingly apparent that the focus needs to be shifted to the translation of the  
409 peptides into commercial functional food products. Studies focused on characterizing the  
410 digestion and release of encapsulated peptides during gastrointestinal processing are crucial in  
411 understanding the effect of encapsulation on biostability. One study evaluated the biostability of  
412 bioactive peptides encapsulated with a carboxymethylated gum and sodium alginate, and found  
413 minimal (up to 10%) and maximal (up to 60%) release of protein materials after simulated  
414 gastric and intestinal digestion phases, respectively.<sup>16</sup> The released peptides at the intestinal  
415 phase can then be presented for absorption into the enterocytes and subsequently into circulation  
416 where they are still susceptible to further peptidolytic modification. Therefore, it is imperative to  
417 assess the digestion kinetics and biostability of encapsulated peptides, and their bioavailability in  
418 different physiological sites to ensure the release of the intact bioactives at appropriate time and  
419 target location.

420

## 421 **7.0. Challenges and future prospects of peptide encapsulation**

422 The heterogeneity of protein hydrolysates containing diverse range of peptides with different net  
423 charge, hydrophobicity, molecular weight and surface properties makes it challenging to achieve  
424 high and uniform EE. Enhancing the EE is particularly important to avoid the use of large  
425 quantities of the encapsulated protein hydrolysates and peptides in attaining the desired amount  
426 of the actual active material.<sup>30</sup> Purifying the peptides from protein hydrolysates can improve the

RSC Advances

427 condition; however, it requires high-end processing techniques that can be uneconomical for  
428 small and medium-sized food industry.<sup>9</sup> However, some techniques are showing promise for use  
429 in purifying peptides or concentrating bioactive fractions at a large scale and low cost.<sup>33,34</sup> Some  
430 promising techniques currently used for the delivery of drug and other bioactive compounds  
431 have the potential to be extended to food protein hydrolysates and peptides. For instance,  
432 proliposomes, which are used for drug delivery, can be used to overcome the quality issues  
433 associated with liposomes such as oxidation, aggregation and phospholipid hydrolysis.<sup>35</sup>

434 Future studies should focus on detailed and balanced evaluation of encapsulated peptides  
435 derived from all the carrier types for biostability, organoleptic properties and bioavailability. The  
436 applicable techniques would have to achieve practical EE without requiring expensive  
437 processing steps and carrier materials. Forthcoming research should also be focused on  
438 understanding the effect of encapsulation on the functionality and stability of encapsulated  
439 peptide products, digestion kinetics, release rate, and compatibility with the food and  
440 physiological matrices. It is noteworthy that spray dried microspheres have been reported to be  
441 highly resistant to mechanical fractures.<sup>5</sup> Although, peptide release from electrostatically-driven  
442 encapsulation (film hydration, coacervation) appear relatively easier to achieve, it is imperative  
443 to characterize the underlying mechanism and release profile of encapsulated peptide products to  
444 facilitate their use in product development. Furthermore, *in vivo* studies using animal models and  
445 human subjects are needed to confirm the effectiveness of encapsulation in enhancing  
446 bioavailability and in retention of bioactivity after oral consumption of the products as food.

447

## 448 **8.0. Conclusion**

RSC Advances

449 Encapsulation of bioactive food compounds is well-positioned to facilitate the design of better  
450 and efficient functional foods. This is essential in advancing the research on bioactive food  
451 protein hydrolysates and peptides and to develop the market of the peptides as natural health  
452 products and nutraceuticals. To achieve high EE, the choice of the carrier material used is  
453 dependent on the encapsulation and processing techniques, environment and chemistry of the  
454 peptides, although more work is needed to delineate the impact of the latter on EE. Apart from  
455 high EE, knowledge of digestion and release kinetics, and the morphology of encapsulated  
456 peptide products is paramount to obtaining applicable functional materials for food formulation.

457

458 **Acknowledgement.** Financial support was provided by the Natural Sciences and Engineering  
459 Research Council of Canada (NSERC). A.M. and S.R.C.K.R. are recipients of the Nova Scotia  
460 Research and Innovation Graduate Scholarships.

461

## 462 **References**

- 463 1. C. P. Champagne and P. Frustier. *Curr. Opin. Biotechnol.*, 2007, 18, 184.
- 464 2. C. C. Udenigwe. *Trends Food Sci. Tech.* 2014, 36, 137.
- 465 3. M. Fathi, Á. Martín and D. J. McClements. *Trends Food Sci. Tech.*, 2014, 39, 18.
- 466 4. D. J. McClements. Nanoparticle-and microparticle-based delivery systems: Encapsulation,  
467 protection and release of active compounds. CRC Press, 2014, 572 pages
- 468 5. S. E. M. Ortiz, A. Mauri, E. S. Monterrey-Quintero, M. A. Trindade, A. S. Santana and C.  
469 S. Favaro-Trindade, *LWT Food Sci. Technol.* 2009,42, 919.
- 470 6. G. Picariello, G. Iacomino, G. Mamone, P. Ferranti, O. Fierro, C. Gianfrani. A. Di Luccia,  
471 and F. Addeo. *Food Chem.*, 2013, 139, 203.

- 472 7. M. Segura-Campos, L. Chel-Guerrero, D. A. Betancur-Ancona, and V. M. Hernandez-  
473 Escalante. *Food Rev. Int.*, 2011, 27, 213.
- 474 8. M. Fathi, M. R. Mozafari and M. Mohebbi. *Trends Food Sci Tech.*, 2012, 23, 13.
- 475 9. G. M. Tavares, T. Croguennec, A. F. Carvalho and S. Bouhallab. *Trends Food Sci. Tech.*,  
476 2014, 37, 5.
- 477 10. J. J. Ma, X. Y. Mao, Q. Wang, S. Yang, D. Zhang, S. W. Chen and Y. H. Li. *LWT. Food*  
478 *Sci. Technol.*, 2014, 56, 296.
- 479 11. Z. Wang, X. Ju, R. He, J. Yuan and L. Wang. *Food Bioprocess Technol.*, 2015, 8, 1305.
- 480 12. M. J. Sáiz-Abajo, C. Monzales-Ferrero, A. Moreno-Ruiz, A. Romo- Huald, and C. J.  
481 Gonzalez-Navarro. *Food Chem.*, 2013, 138, 1581.
- 482 13. G. J. O'Neill, T. Egan, J. C. Jacquier, M. O'Sullivan and E. D. O'Riordan. *Food Chem.*,  
483 2014, 160, 46.
- 484 14. G. J. O'Neill, T. Egan, J. C. Jacquier, M. O'Sullivan and E. D. O'Riordan. *Food Chem.*,  
485 2015, 180, 150.
- 486 15. C. S. Favaro-Trindade, A. S. Santana, E. S. Monterrey-Quintero, M. A. Trindade and F. M.  
487 Netto. *Food Hydrocolloids*, 2010, 24, 336.
- 488 16. J. C. Ruiz Ruiz, M. R. Segura Campos, D. A. Betancur-Ancona, and L. A. Chel-Guerro  
489 *ISRN Biotech.*, 2013.
- 490 17. D. Yokota, M. Moraes and S. C. Pinho. *Braz. J. Chem. Eng.*, 2012, 29, 325.
- 491 18. L. E. Kurosawa, K. J. Park and M. D. Hubinger. *J. Food Eng.*, 2009, 94, 326.
- 492 19. C. Barbosa. H. A. Morais, F. M. Delvivo, H. S. Mansur, M. C. De Oliveira and M. P.  
493 Silvestre. *J. Sci. Food. Agri.*, 2004, 84, 1891.
- 494 20. J. C. Silva and S.C. Pinho. *Int. J. Food Stud.*, 2013, 2, 48.

RSC Advances

- 495 21. J.A.A. Zhang and J. Pawelchak. *Eur. J. Pharm. Biopharm.*, 2000, 50, 357.
- 496 22. B. Zhang and X. Zhang. *Biotechnol. Prog.*, 2014, 29, 1230.
- 497 23. S. Yang, X. Y. Mao, F. F. Li, D. Zhang, X. J. Leng, F. Z. Ren and G. X. Teng. *Eur. Food*  
498 *Res. Technol.* 2012, 235, 91.
- 499 24. M. Mosquera, B. Giménez, I. M. da Silva, J. F. Boelter, P. Montero, M. C. Gómez-Guillén  
500 and A. Brandelli. *Food Chem.*, 2014, 156, 144.
- 501 25. E. Da Rosa Zavareze, A. C. Telles, S. L. Mello El Halal, M. Da Rocha, R. Colussi, L. M.  
502 De Assis, L. A. S. De Castro, A. R. G. Dias and C. Prentice-Hernandez. *LWT Food Sci.*  
503 *Technol.*, 2014, 59, 841.
- 504 26. H. A. Morais, C. M. Da Silva Barbosa, F. M. Delvivo, H. S. Mansur, M. C. De Oliviera and  
505 M. P. C. Silvestre. *J. Food Biochem.*, 2004, 28, 21.
- 506 27. W. Liu, A. Ye, C. Liu, J. Han and H. Singh. *Food Chem.*, 2015, 175, 16.
- 507 28. C. M. D. S. Barbosa, H. A. Morais, D. C. F. Lopes, H. S. Mansur, M. C. D. Oliveira and M.  
508 P. C Silvestre. *Braz. J. Pharm. Sci.*, 2002, 38, 361.
- 509 29. S. F. Subtil, G. A. Rocha-Selmi, M. Thomazini, M. A. Trindade, F. M. Netto and C. S.  
510 Favaro-Trindade. *J. Food Sci. Technol.*, 2014, 51, 2014.
- 511 30. G. A. Rocha., M. A. Trindade, F. M. Netto and C. S. Favaro-Trindade. *Food Sci. Technol.*  
512 *Int.*, 2009, 15, 407
- 513 31. S. Gouin. *Trends Food Sci. Tech.*, 2004, 15, 330.
- 514 32. D. V. Mendanha, S. E. M. Ortiz, C. S. Favaro-Trindade, A. Mauri, E. Monterrey-Quintero  
515 and M. Thomazini. *Food. Res. Int.*, 2009, 42, 1099.
- 516 33. L. Bazinet, and L. Firdaous. *Recent Patents on Biotechnology*, 2013, 7, 9.



RSC Advances

517 34. A. Doyen, C. C. Udenigwe, P. L. Mitchell, A. Marette, R.E. Aluko, and L. Bazinet. *Food*  
518 *Chem.*, 2014, 145, 66.

519 35. B. Zheng, L. Teng, G. Xing, Y. Bi, S. Yang, F. Hao, G. Yan, X. Wang, R. J. Lee, L.Teng  
520 and J. Xie. *Eur. J. Pharm. Sci.*, 2015, 77, 254.

521

522

523

524

525


526

527

528

529

RSC Advances Accepted Manuscript



530

531 Fig. 1. Carriers used for encapsulation of protein hydrolysates and peptides

532

533

534

535

536

537

538

539

540

RSC Advances

541

RSC Advances Accepted Manuscript

RSC Advances

Table 1. Encapsulation of food protein hydrolysates and peptides using protein, polysaccharide and lipid carriers

	Hydrolysate/peptide	Core to wall ratio (w/w)	EE (%)	Size (µm)	Methodology	Ref
<i>Protein matrix</i>						
SPI	CH	2:8 and 3:7	-	9-11	Pre-dissolved SPI and CH mixed and homogenized followed by spray drying.	[5]
SPI + Pectin	CH	1:1:1; 1:1:2; 1:1:3	78-91	16-24	Coacervation: Aqueous CH was emulsified in soy oil to form w/o emulsion followed by emulsification in SPI at pH 8 to form o/w emulsion. Pectin slowly added to w/o/w emulsion and pH reduced to 4.4 at 40°C. Coacervated material stored at 7°C and later freeze dried.	[32]
SPI + gelatin	CH	3:7 and 2:7	-	10-17	SPI dispersed in water at pH 8 was mixed with gelatin and then was homogenized with CH followed by spray drying.	[15]
WPC and WPC + sodium alginate	WPC hydrolysate	3:7	-	-	WPC and sodium alginate separately dissolved; WPC hydrolysate added under agitation until dissolved and spray dried; freeze dried or mechanically blended.	[10]
RPI	Rapeseed peptides	1:1, 1:2 and 2:1	63-99	5-16	Pre-dissolved native, acylated or high pressure-treated RPI was adjusted to pH 11.0, followed by the addition of the peptides and spray drying of the mixture.	[11]
		0.2 <sup>a</sup>	32	-		[13]
	Phe-Trp	0.4 <sup>a</sup>	56	-	Peptides (0.2 g/L) were mixed with WPI microbeads (0.2 g) at volume ratios of 0.013-0.2 (bead-to-peptide solution). Mixtures were then stirred for 24 h.	[14]
WPI	Leu-Trp-Met-Arg-Phe	0.2 <sup>a</sup>	89	-	Encapsulation efficiency was dependent on volume ratio.	[13]
		0.4 <sup>a</sup>	95	-		[14]
<i>Polysaccharide matrix</i>						
MD + gum arabic	Chicken hydrolysate	10: (1-3)	-	5-20	MD and gum arabic directly added to the hydrolysate and then spray dried.	[18]
MD	CH	1:9	-	13-15	Pre-dissolved MD and CH mixed and homogenized followed by spray drying.	[30]

## RSC Advances

Carboxymethylated gum + sodium alginate (1:1)	Hydrolysate of <i>Phaseolus lunatus</i>	4:3	53-78	-	Gum and hydrolysate dispersed in water which was dropped into CaCl <sub>2</sub> solution to form beads. Beads were allowed to harden for 30 min.	[16]
Gum arabic	CH	1:9; 2:8; 3:7	-	16-20	Aqueous solution of gum and CH prepared followed by spray drying.	[28]
MD + cyclodextrin (1:1)	Whey protein hydrolysate	3:7	-	2.47	MD and CD were separately dispersed in water (pH 7) and mixed together with the hydrolysate, rotary evaporated and spray dried.	[23]
Chitosan	Polypeptide ( <i>Spirulina platensis</i> )	1:2	49	0.15	Ionotropic gelation: Chitosan dissolved in acetic acid, centrifuged and polypeptide solution added. TPP added and stirred for 60 min and oven dried.	[21]
<i>Liposome matrix</i>						
PC	<i>Micropogonias furnieri</i> (fish) hydrolysate	1:5	80	0.263-0.266	Phospholipid (PL) dissolved in organic solvent and evaporated followed by hydration using hydrolysate in buffer. Heating, stirring, vortexing and sonicating in cycles.	[25]
PC	Sea bream scales collagen peptide fraction	1:31	74.6	0.066-0.21 nm	PL dissolved in organic solvent and evaporated followed by hydration with hydrolysate sample dissolved in buffer. Encapsulation by sonication.	[24]
PC + PG + cholesterol	CH	-	56-62	0.5-1.0	PL dissolved in organic solvent and evaporated followed by hydration using sample dissolved in buffer and EDTA. Encapsulation by sonication.	[26]
Lecithin	CH	1:7.5	30-46	0.5-5.0	Similar to Morais et al. <sup>22</sup> Also used sucrose as a cryoprotectant. Encapsulation by agitation and sonication.	[17]
<i>Liposphere matrix</i>						
Stearic acid + PC	CH	-	66	3.8	CH was added to melted stearic acid followed by the addition of PC pre-dissolved in buffer. Mixture was homogenized to form an emulsion and rapidly cooled to 20°C.	[27]
Stearic acid + PC	CH	-	50-83	5.0		[19]

## RSC Advances

Stearic acid + PC	CH	-	50-83	5.0		[26]
Stearic acid + cupuacu butter	CH	-	73.9	2-10	Melted lipid phase (80% stearic acid + 20% cupuacu butter) was mixed with 4% polysorbate 80 at 80°C with agitation followed by cooling of the emulsion system to 20°C.	[20]

<sup>a</sup>Represent volume ratios (i.e.  $V_{\text{bead}}/V_{\text{aq}}$ , where  $V_{\text{bead}}$  is the volume of the protein microbeads and  $V_{\text{aq}}$  is the volume of the peptide solution  
Soy protein isolate, SPI; casein hydrolysate, CH; whey protein concentrate, WPC; rapeseed protein isolate, RPI; whey protein isolate, WPI; maltodextrin, MD; phosphatidyl choline, PC; phosphatidyl glycine, PG

---